Table 2.

Characteristics of patients who developed anaphylaxis with rhGAA and underwent RDD

Case no.	Age at development of anaphylaxis, months	Present age, months	Initial reaction, signs, and symptoms	Type of anaphylaxis	Anaphylaxis developing dose	Administered dose and frequency when anaphylaxis develops	Infusion rate of developing anaphylaxis, mg/kg/min	RDD starting dose	RDD time, h	RDD performed, n
1	7	122	Urticaria, irritability, intractable cough, itching, stridor	Type I IgE mediated	11th	20 mg/kg Biweekly	0.016	1/1,000,000	11.7	264
2	5	34	Irritability, tachypnea, desaturation, cyanosis, fever, urticaria	Mixed type	8th	40 mg/kg Biweekly	0.116	1/500,000	19.6	56
3	48	72	Abdominal pain, recurrent vomiting, intractable cough	Type I IgE/non-IgE mediated	86th	40 mg/kg Biweekly	0.041	1/648,000	9.4	39
4	49	62	Urticaria, angioedema, tachypnea, cyanosis	Type I IgE/non-IgE mediated	10th	40 mg/kg Weekly	0.083	1/560,000	12	31

rhGAA, recombinant alglucosidase alfa; RDD, rapid drug desensitization.